# Extracorporeal membrane oxygenation therapy for severe influenza-associated pulmonary aspergillosis: a case report

**Authors:** Cuijie Tian, Chaofan Liang, Xinyan Zhang, Xiaoju Zhang

PMC · DOI: 10.3389/fmed.2026.1732770 · Frontiers in Medicine · 2026-02-24

## TL;DR

This case report describes the successful use of ECMO and bronchoscopic treatment for a severe case of influenza-associated pulmonary aspergillosis.

## Contribution

The paper presents a novel case of IAPA managed with VV-ECMO and bronchoscopic antifungal therapy.

## Key findings

- VV-ECMO was used as a bridge to diagnostic bronchoscopy in a patient with severe IAPA.
- Combination of systemic and bronchoscopic antifungal therapy improved clinical outcomes.
- The patient was successfully weaned from ECMO and discharged after treatment.

## Abstract

Influenza-associated pulmonary aspergillosis (IAPA) is an increasingly recognized life-threatening condition in non-classically immunocompromised hosts. This report describes the clinical course and management of severe IAPA involving significant airway invasion.

A 34-year-old female presented with a 1-week history of fever and rapidly progressive dyspnea. Laboratory testing confirmed influenza A (H1N1) infection and significantly elevated serum galactomannan (GM) index 5.436. Despite invasive mechanical ventilation, the patient developed refractory acute respiratory failure (ARF) characterized by extreme airway resistance (190 cmH2O/L/s) and extensive subcutaneous emphysema. Veno-venous extracorporeal membrane oxygenation (VV-ECMO) was initiated as a bridge to facilitate diagnostic bronchoscopy, which revealed extensive necrotic pseudomembrane. Subsequent BALF microscopy and mNGS confirmed Aspergillus fumigatus coinfection with Influenza A (H1N1), establishing the diagnosis of IAPA. Management involved a combination of systemic and localized bronchoscopic antifungal therapy (Amphotericin B) and iterative airway clearance. Despite complications including secondary extensively drug-resistant Pseudomonas aeruginosa infection and suspected drug-induced hemolysis, the patient was successfully weaned from ECMO on 22 March 2023 and eventually discharged following clinical improvement.

VV-ECMO combined with repeated bronchoscopic interventions can serve as a rescue strategy in selected patients with airway-invasive IAPA and refractory respiratory failure.

## Linked entities

- **Chemicals:** Amphotericin B (PubChem CID 1972)
- **Diseases:** acute respiratory failure (MONDO:0001208)
- **Species:** Aspergillus fumigatus (taxon 746128)

## Full-text entities

- **Diseases:** necrotic (MESH:D009336), subcutaneous emphysema (MESH:D013352), Pseudomonas aeruginosa infection (MESH:D011552), fever (MESH:D005334), hemolysis (MESH:D006461), ARF (MESH:D012131), dyspnea (MESH:D004417), influenza A (H1N1) infection (MESH:D007251), IAPA (MESH:D055732)
- **Chemicals:** Amphotericin B (MESH:D000666), Extracorporeal (-), GM (MESH:C012990)
- **Species:** Homo sapiens (human, species) [taxon 9606], H1N1 subtype (serotype) [taxon 114727], Aspergillus fumigatus (species) [taxon 746128]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12971974/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12971974/full.md

## References

9 references — full list in the complete paper: https://tomesphere.com/paper/PMC12971974/full.md

---
Source: https://tomesphere.com/paper/PMC12971974